Novartis has put a new strategy into place for its innovative medicines business in order to spur product development and cut costs. The changes will create separate commercial organisations for the US and elsewhere while integrating the group’s corporate, R&D and business development activities for proprietary medicines as a single function. The reorganisation will not affect Novartis’ generics business unit Sandoz which is undergoing a separate strategic review, the company told MedNous.
